Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutations or RAD51-foci low test: RADIOLA TRIAL
Latest Information Update: 20 Apr 2023
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms RADIOLA TRIAL
Most Recent Events
- 17 Apr 2023 Planned number of patients changed from 66 to 63.
- 17 Apr 2023 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.
- 17 Apr 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Apr 2024.